Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

Review decision: May 2012 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 111 KB)

Prostate cancer (hormone-refractory) - docetaxel: review proposal - March 2012 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 56 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 114 KB)

Review decision - August 2009 information

Review decision - August 2009: appendix A - decision paper

Review decision - August 2009: appendix A - decision paper (PDF 58 KB)

Review proposal - June 2009 information

Provisional matrix of consultees and commentators

Prostate cancer (hormone-refractory) - docetaxel: Consultee and commentator comments on the ACD 

British Prostate Group

British Prostate Group (PDF 50 KB)

Department of Health

Department of Health (PDF 13 KB)

Institute of Cancer Research

Institute of Cancer Research (PDF 80 KB)

NHS Quality Improvement

NHS Quality Improvement (PDF 27 KB)

Prostate Cancer Charity

Prostate Cancer Charity (PDF 44 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 67 KB)

Sanofi Aventis

Sanofi Aventis (PDF 125 KB)

Welsh Assembly Government

Waxman

Prostate cancer (hormone refractory) - docetaxel (final appraisal determination) information

Response to consultee, commentator and public comments on the ACD

Prostate cancer (hormone-refractory) - docetaxel: overview

Prostate cancer (hormone-refractory) - docetaxel - Assessment report addendum

Prostate cancer (hormone-refractory) - docetaxel: assessment report

Prostate cancer (hormone-refractory) - docetaxel: Consultee and commentator comment on the assessment report

British Prostate Cencer Group

British Prostate Cencer Group (PDF 67 KB)

Cancer BACUP

Cancer BACUP (PDF 16 KB)

Institute of Cancer Research

Institute of Cancer Research (PDF 59 KB)

NHS Quality Improvement Scotland

NHS Quality Improvement Scotland (PDF 33 KB)

Prostate Cancer Charity

Prostate Cancer Charity (PDF 57 KB)

Prostate Cancer Guideline Group

Prostate Cancer Guideline Group (PDF 14 KB)

Royal College of Nursing

Royal College of Nursing (PDF 17 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 15 KB)

Royal College of Physicians

Royal College of Physicians (PDF 44 KB)

Sanofi-Aventis (Formerly known as Aventis Pharma Ltd)

Prostate cancer (hormone-refractory) - docetaxel: non manufacturer submissions

Cancer BACUP

Cancer BACUP (PDF 39 KB)

Royal College of Nursing

Royal College of Nursing (PDF 15 KB)

Royal College of Pathologists

Royal College of Pathologists (PDF 14 KB)

Royal College of Physicians, the Association of Cancer Physicians, the Royal College of Radiologists and the Joint Collegiate Council for Oncology (joint submission

Sanofi-Aventis (Formerly known as Aventis Pharma Ltd)

Prostate cancer (hormone-refractory) - docetaxel: Final protocol

Prostate cancer (hormone-refractory) - docetaxel: Final scope

Prostate cancer (hormone-refractory) - docetaxel: Summary of consultee and commentator comments of the draft scope

Prostate cancer (hormone-refractory) - docetaxel: Summary of consultee and commentator comments on the draft matrix 

Prostate cancer (hormone-refractory) - docetaxel: draft scope

Prostate cancer (hormone-refractory) - docetaxel: provisional matrix of consultees and commentators